Application
Western blot analysis of extracts from HT29 cells untreated or treated with Anisomycin using eIF4G (phospho-Ser1232) AntibodyApplication
Western blot analysis of extracts from HT29 cells untreated or treated with Anisomycin using eIF4G (phospho-Ser1232) Antibody .Application
Immunohistochemical analysis of paraffin-embedded human lung carcinoma tissue using eIF4G (Phospho-Ser1232) Antibody (left) or the same antibody preincubated with blocking peptide (right).| Product Name | eIF4G (phospho Ser1232) antibody |
|---|---|
| Antibody Type | Primary Antibodies |
| Product description | Rabbit Polyclonal antibody to eIF4G (Phospho Ser1232)eIF4F is a multi-subunit complex, the composition of which varies with external and internal environmental conditions. It is composed of at least EIF4A, EIF4E and EIF4G1/EIF4G3. Interacts with eIF3, mutually exclusive with EIF4A1 or EIFA2, EIF4E and through its N-terminus with PAPBC1. Interacts through its C-terminus with the serine/threonine kinases MKNK1, and with MKNK2. Appears to act as a scaffold protein, holding these enzymes in place to phosphorylate EIF4E. Non-phosphorylated EIF4EBP1 competes with EIF4G1/EIF4G3 to interact with EIF4E; insulin stimulated MAP-kinase (MAPK1 and MAPK3) phosphorylation of EIF4EBP1 causes dissociation of the complex allowing EIF4G1/EIF4G3 to bind and consequent initiation of translation. EIF4G1/EIF4G3 interacts with PABPC1 to bring about circularization of the mRNA. Rapamycin can attenuate insulin stimulation mediated by FKBPs. Interacts with EIF4E3. Interacts with MIF4GD. Interacts with rotavirus A NSP3; in this interaction, NSP3 takes the place of PABPC1 thereby inducing shutoff of host protein synthesis |
| Immunogen | Peptide sequence around phosphorylation site of serine 1232 (P-V-S(p)-P-L) derived from Human eIF4G. |
| Modification | p-Ser1232 |
| Clonality | Polyclonal |
|---|---|
| Host Species | Rabbit |
| Tested Applications | IHC-PWB |
| Suggested starting dilutions are as follows. WB: 1:500~1:1000, IHC-P: 1:50~1:100. Not yet tested in other applications. Optimal working dilutions should be determined experimentally by the end user.: |
|
| Species Reactivity | Human |
| Concentration | 1mg/ml (Please refer to the vial label for the specific concentration) |
| Purification | Affinity purified |
| Gene Synonyms | DKFZp686A1451 EIF-4G1 EIF4F EIF4G EIF4GI P220 EIF4G1 eucaryotic translation initiation factor 4G EIF4-gamma eukaryotic translation initiation factor 4 gamma 1 eIF-4-gamma 1 eukaryotic translation initiation factor 4 gamma 1 |
|---|---|
| Target | eIF4G (Phospho Ser1232) |
| Molecular Weight(MW) | 220 (note) |
Application
Western blot analysis of extracts from HT29 cells untreated or treated with Anisomycin using eIF4G (phospho-Ser1232) Antibody
Application
Western blot analysis of extracts from HT29 cells untreated or treated with Anisomycin using eIF4G (phospho-Ser1232) Antibody .
Application
Immunohistochemical analysis of paraffin-embedded human lung carcinoma tissue using eIF4G (Phospho-Ser1232) Antibody (left) or the same antibody preincubated with blocking peptide (right).| Application Notes | Suggested starting dilutions are as follows. WB: 1:500~1:1000, IHC-P: 1:50~1:100. Not yet tested in other applications. Optimal working dilutions should be determined experimentally by the end user.: |
|---|
| Form | Liquid |
|---|---|
| Storage Instructions | Keep as concentrated solution. Aliquot and store at -20ºC or below. Avoid multiple freeze-thaw cycles. |
| Storage Buffer | saline (without Mg2+ and Ca2+), pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. |
